Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABCL992
- Development stage
- Preclinical
- Lead developer
- AbCellera Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
ABCL992 is an investigational, next-generation monoclonal antibody targeting the neurokinin-3 receptor (NK3R). Developed by AbCellera, it is a half-life-extended analog of ABCL635 designed for less frequent dosing (such as once-monthly or every three months) to treat moderate and severe vasomotor symptoms (VMS, or menopausal hot flashes). NK3R is a complex transmembrane protein located on KNDy neurons in the hypothalamus that helps regulate body temperature. ABCL992 entered IND-enabling activities in Q3 2026 and is expected to reach clinical development in 2028.
02
Targets
Beyond the preview
Go deeper on ABCL992.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABCL992.
Work on ABCL992? Claim this page to correct or add information. Claim this page